Severe Hypertriglyceridemia Indication Strategy Report 2026: APOC3, ANGPTL3 and Trials uses PatSnap MCP evidence to evaluate disease burden, target rationale, clinical competition, transaction signals, unmet need and market attractiveness for one indication only.

Familial Hypercholesterolemia Indication Strategy Report 2026: PCSK9, LDLR, Trials and Deals uses PatSnap MCP evidence to evaluate disease burden, target rationale, clinical competition, transaction signals, unmet need and market attractiveness for one indication only.

Type 1 Diabetes Indication Strategy Report 2026: CD3, Cell Therapy, Trials and Deals uses PatSnap MCP evidence to evaluate disease burden, target rationale, clinical competition, transaction signals, unmet need and market attractiveness for one indication only.

Type 2 Diabetes Indication Strategy Report 2026: GLP-1R, SGLT2, Trials and Deals uses PatSnap MCP evidence to evaluate disease burden, target rationale, clinical competition, transaction signals, unmet need and market attractiveness for one indication only.

Adult Obesity Indication Strategy Report 2026: GLP-1R, GIPR, Trials and Deals uses PatSnap MCP evidence to evaluate disease burden, target rationale, clinical competition, transaction signals, unmet need and market attractiveness for one indication only.

Liver Transplant Rejection Indication Strategy Report 2026: CD40, Trials and Market Signals uses PatSnap MCP evidence to evaluate disease burden, target rationale, clinical competition, transaction signals, unmet need and market attractiveness for one indication only.

Kidney Transplant Rejection Indication Strategy Report 2026: CD40, Trials and Deals uses PatSnap MCP evidence to evaluate disease burden, target rationale, clinical competition, transaction signals, unmet need and market attractiveness for one indication only.

GVHD Indication Strategy Report 2026: JAK1, ROCK2, Trials and Deals uses PatSnap MCP evidence to evaluate disease burden, target rationale, clinical competition, transaction signals, unmet need and market attractiveness for one indication only.

Primary Sclerosing Cholangitis Indication Strategy Report 2026: FXR, CCR2, Trials and Deal Outlook uses PatSnap MCP evidence to evaluate disease burden, target rationale, clinical competition, transaction signals, unmet need and market attractiveness for one indication only.

Primary Biliary Cholangitis Indication Strategy Report 2026: PPARδ, FXR, Trials and Deals uses PatSnap MCP evidence to evaluate disease burden, target rationale, clinical competition, transaction signals, unmet need and market attractiveness for one indication only.

Autoimmune Hepatitis Indication Strategy Report 2026: CD20, IL-6, Trials and Deals uses PatSnap MCP evidence to evaluate disease burden, target rationale, clinical competition, transaction signals, unmet need and market attractiveness for one indication only.

Pemphigus Vulgaris Indication Strategy Report 2026: CD20, FcRn, Trials and Deal Outlook uses PatSnap MCP evidence to evaluate disease burden, target rationale, clinical competition, transaction signals, unmet need and market attractiveness for one indication only.